ADULT: CORONARY: LETTERS TO THE EDITOR



CLAMPLESS FACILITATED ANASTOMOSIS WITH HEARSTRING TO REDUCE CEREBRAL DAMAGE DURING OFF-PUMP CORONARY BYPASS

GRAFTING. DON'T FORGET IT: EASY TO USE!

To the Editor:

In their prospective randomized study, Halkos and colleagues¹ highlight a strategy to reduce the risk of cerebral embolism during on-pump and off-pump aortic coronary bypass grafting (CABG) surgery. The authors compared 4 groups of patients according to the surgical technique used. Because of the low number of patients in each group, the main purpose of the study was to detect the high-intensity transient signals (HITS) by transcranial Doppler ultrasonography instead of the incidence of major neurologic events such as cerebral stroke. Indeed, the authors reported postoperative cerebral stroke in 2 patients of single-clamp subgroup, although these events occurred after the first postoperative day in patients already extubated and the number of HITS were not outliers compared with the other patients. In addition, neurocognitive tests did not yield useful data because they were available only for a small number of patients. The authors have finally shown that patients in whom the HEARTSTRING device (Maquet Cardiovascular, San Jose, Calif) was used had more HITS than patients who underwent the partial clamping technique and the number of HITS increased proportionally to the number of HEARTSTRING devices used for each patient.

Despite the great value of this prospective randomized study, the small number of patients included did not allow the authors to demonstrate whether the use of HEARTSTRING really places patients at risk of developing postoperative stroke in the real world, bearing in mind that gaseous emboli occurred more frequently than solid with the HEARTSTRING² and therefore the incidence of stroke could be dramatically reduced. Unfortunately, the authors were not able to differentiate between solid and gaseous emboli.

In a retrospective analysis of 412 HEARTSTRING patients, Hilker and colleagues³ reported 2 stroke events (0.48%), which were below the predicted value of 1.3% of their studied population. Zhao and colleagues⁴ conducted a meta-analysis on 37,720 patients with the aim of verifying the incidence of stroke according to the techniques used. Off-pump CABG was associated with a 76% reduction in stroke compared with conventional CABG, and the use of HEARTSTRING was associated with a significant 56% reduction, whereas the partial clamp showed the lowest reduction. The data reported by Halkos and colleagues¹ in this study are of paramount importance to guide the surgeon to the more appropriate surgical technique in patients with

high predictive risk for postoperative stroke.

The ideal technique remains the anaortic one. When this technique cannot be used, the clampless anastomosis with HEARTSTRING should be considered and should be part of the armamentarium of each cardiac surgeon, also considering the simplicity of the technique itself. We fully agree with the authors that with the HEARTSTRING device there is still a manipulation of the ascending aorta. A blower-mister device is often used to enhance visualization during construction of the anastomosis. This can increase the risk of cerebral microembolization, although most of the microemboli may occur during the application and the removal of the device. Despite these limits, HEARTSTRING remains a useful tool, especially in patients with moderate- or high-grade ascending aorta disease, as reported by the same authors.

Francesco Formica, MD^a
Stefano D'Alessandro, FECTS, MD^a
Luigi Amerigo Messina, MD^b

^aCardiac Surgery Unit
Department of Medicine and Surgery
San Gerardo Hospital
University of Milano-Bicocca
Monza, Italy

^bStatistics and Quality Health Service
San Gerardo Hospital
Monza, Italy

References

- Halkos ME, Anderson A, Binongo JNG, Stringer A, Lasanajak Y, Thourani VH, et al. Operative strategies to reduce cerebral embolic events during on- and off-pump coronary artery bypass surgery: a stratified, prospective randomized trial. J Thorac Cardiovasc Surg. 2017;154:1278-85.
- Guerrieri Wolf L, Abu-Omar Y, Choudhary BP, Pigott D, Taggart DP. Gaseous and solid cerebral microembolization during proximal aortic anastomoses in off-pump coronary surgery: the effect of an aortic side-biting clamp and two clampless devices. J Thorac Cardiovasc Surg. 2007;133:485-93.
- Hilker M, Arlt M, Keyser A, Schopka S, Klose A, Diez C, et al. Minimizing the risk of perioperative stroke by clampless off-pump bypass surgery: a retrospective observational analysis. J Cardiothorac Surg. 2010;25:5-14.
- Zhao DF, Edelman JJ, Seco M, Bannon PG, Wilson MK, Byrom MJ, et al. Coronary artery bypass grafting with and without manipulation of the ascending aorta: a network meta-analysis. J Am Coll Cardiol. 2017;69:924-36.

The Editor welcomes submissions for possible publication in the Letters to the Editor section that consist of commentary on an article published in the Journal or other relevant issues. Authors should: • Include no more than 500 words of text, three authors, and five references. • Type with double-spacing. • See http://jtcs.ctsnetjournals.org/misc/ifora.shtml for detailed submission instructions. • Submit the letter electronically via jtcvs.editorialmanager.com. Letters commenting on an article published in the JTCVS will be considered if they are received within 6 weeks of the time the article was published. Authors of the article being commented on will be given an opportunity of offer a timely response (2 weeks) to the letter. Authors of letters will be notified that the letter has been received. Unpublished letters cannot be returned.

Authors have nothing to disclose with regard to commercial support.

 Thourani VH, Razavi SA, Nguyen TC, Kilgo PD, Puskas JD, Guyton RA, et al. Incidence of postoperative stroke using the Heartstring device in 1,380 coronary artery bypass graft patients with mild to severe atherosclerosis of the ascending aorta. Ann Thorac Surg. 2014;97:2066-72.

https://doi.org/10.1016/j.jtcvs.2017.11.038



USE OF CLAMPLESS FACILITATING DEVICES IN PATIENTS WITH LOW-GRADE AORTIC DISEASE: IS THE COST JUSTIFIED BY THE THEORETIC RISK REDUCTION?



Reply to the Editor:

I appreciate the commentary of Formica and colleagues regarding the use of clampless facilitating devices (CFDs) in patients undergoing coronary artery bypass grafting (CABG). The quest to reduce stroke after CABG has led to numerous observational and prospective trials with a variety of approaches, including off-pump CABG, anaortic approaches, hybrid revascularization, and CFDs. With regard to my group's recent prospective, randomized trial, 1 we agree with Formica and colleagues that there were limitations with our study, specifically that the primary end point was a surrogate for stroke, transcranial Doppler high-intensity transient signals (HITS) rather than a hard clinical end point. Nonetheless, we anticipated a reduction in HITS in the CFD group, supporting the use of these devices, but the results did not support our hypothesis. Selection bias, which is a major limitation of many observational studies, including those from our own institution,² was minimized in this study with randomization.

Nonetheless, what our randomized, controlled trial did show was that HITS increased proportionally to the number of devices used and that the total numbers of gaseous and solid HITS detected were higher in the CFD group than in the partial-clamp group. I agree with Formica and colleagues that many of these HITS may have represented gaseous rather than solid microemboli, but the transcranial Doppler technology used in this trial was insufficiently sensitive to differentiate reliably the two. Furthermore, I agree that transcranial Doppler technology is associated with its own limitations.

The current issue is whether patients with low-grade aortic disease in whom CABG is performed off pump truly benefit from the use of CFDs. This is not the same as an anaortic approach, which I also agree is probably associated with the lowest stroke risk. It is important to acknowledge

Author has nothing to disclose with regard to commercial support.

that this trial excluded patients with more advanced aortic disease (grade III-V), because our current practice is to avoid any clamping of these aortas. The use of epiaortic ultrasonography in this study allowed us to evaluate a homogeneous group of patients undergoing CABG. In addition, because of the current climate of cost containment, it is important to consider that the cost of each Heartstring device (MAQUET Holding B.V. & Co. KG, Rastatt, Germany) to the hospital is approximately \$500 to \$700, without a clearly defined benefit in the patient population that was studied.

Our recommendations on the basis of our results was that for patients undergoing off-pump CABG with low-grade aortic (grade I-II) disease, as determined by epiaortic ultrasonography, there was no observed benefit in HITS between patients randomized to receive CFDs versus partial clamping of the aorta. Clearly, surgical decision making in the operating room is needed to determine the best proximal anastomosis strategy for patients undergoing CABG, and we agree that CFDs are an important tool when clinically indicated.

Michael E. Halkos, MD, MSc Division of Cardiothoracic Surgery Emory University School of Medicine Atlanta, Ga


References

- 1. Halkos ME, Anderson A, Binongo JN, Stringer A, Lasanajak Y, Thourani VH, et al. Operative strategies to reduce cerebral embolic events during on- and off-pump coronary artery bypass surgery: a stratified, prospective randomized trial. *J Thorac Cardiovasc Surg.* 2017;154:1278-85.e1.
- Thourani VH, Razavi SA, Nguyen TC, Kilgo PD, Puskas JD, Guyton RA, et al. Incidence of postoperative stroke using the Heartstring device in 1,380 coronary artery bypass graft patients with mild to severe atherosclerosis of the ascending aorta. Ann Thorac Surg. 2014;97:2066-72.

https://doi.org/10.1016/j.jtcvs.2018.01.035



A TUG ON THE HEARTSTRINGS Reply to the Editor:



Embolic Events During On- and Off-Pump Coronary Bypass Surgery:

A Stratified, Prospective Randomized Trial" by Halkos and colleagues¹ from Emory University School of Medicine, a letter to the editor was submitted by Drs Formica, D'Alessandro, and Amerigo Messina² from